{
  "id": 19658620,
  "title": "SpyGlass at Stifel 2026 Healthcare Conference: data, scale and reach",
  "url": "https://urgent.news/2026/11/12/spyglass-at-stifel-2026-healthcare-conference-data-scale-and-reach",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-12T14:05:55.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/spyglass-at-stifel-2026-healthcare-conference-data-scale-and-reach-93CH-5022076"
  },
  "original_language": "en",
  "account": null,
  "summary": "SpyGlass (SGP) highlighted steady progress across its pipeline and operations at the Stifel 2026 Healthcare Conference, six months after going public. The company showcased strong long-term data for its lead eye implant, the BIM-IOL, which demonstrated that 86% of patients remained off topical glaucoma medicine and 90% had visual acuity of 20/25 or better at four years. Additionally, SpyGlass announced a manufacturing deal to improve quality and supply control, as well as a new device called BIM-DRS, designed to expand its market beyond cataract surgery. The company also acquired Advanced Vision Science to bring lens manufacturing in-house, supporting future product development. CEO Patrick emphasized that SpyGlass has advanced in a measured way since its founding in 2019, with four private funding rounds and an initial public offering earlier in the year. The main commercial competition, according to Patrick, is topical drop therapy, not other surgical products, in a market with about 1 million annual U.S. cataract procedures involving glaucoma or ocular hypertension.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}